

Borwin Bandelow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8383426/publications.pdf>

Version: 2024-02-01

157
papers

11,023
citations

36271

51
h-index

33869

99
g-index

189
all docs

189
docs citations

189
times ranked

10134
citing authors

#	ARTICLE	IF	CITATIONS
1	The German Guidelines for the treatment of anxiety disorders: first revision. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 571-582.	1.8	25
2	Chronic Pain and the Endocannabinoid System: Smart Lipids – A Novel Therapeutic Option?. <i>Medical Cannabis and Cannabinoids</i> , 2022, 5, 61-75.	1.2	8
3	Internet psychotherapeutic interventions for anxiety disorders – a critical evaluation. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	3
4	Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients. <i>Human Psychopharmacology</i> , 2021, 36, e2800.	0.7	8
5	The myth that psychotherapy is more effective than pharmacotherapy in anxiety disorders. <i>European Neuropsychopharmacology</i> , 2021, 49, 116-118.	0.3	1
6	Mean age and gender distribution of patients with major mental disorders participating in clinical trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 655-659.	1.8	11
7	A neurobiological framework of separation anxiety and related phenotypes. <i>European Neuropsychopharmacology</i> , 2020, 33, 45-57.	0.3	14
8	Current and Novel Psychopharmacological Drugs for Anxiety Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1191, 347-365.	0.8	55
9	Efficacy of venlafaxine extended release in major depressive disorder patients. <i>International Clinical Psychopharmacology</i> , 2019, 34, 110-118.	0.9	11
10	Network analyses to rank pharmacological treatments for generalised anxiety disorder. <i>Lancet</i> , The, 2019, 393, 721-722.	6.3	0
11	Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. <i>BMC Psychiatry</i> , 2019, 19, 393.	1.1	19
12	WFSBP guidelines on how to grade treatment evidence for clinical guideline development. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 2-16.	1.3	26
13	Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2019, 214, 42-51.	1.7	83
14	Grey matter structural differences in alcohol-dependent individuals with and without comorbid depression/anxiety – an MRI study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 285-294.	1.8	11
15	Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. <i>British Journal of Psychiatry</i> , 2018, 212, 333-338.	1.7	46
16	Comparison of the DSM – 5 and ICD – 10: panic and other anxiety disorders. <i>CNS Spectrums</i> , 2017, 22, 404-406.	0.7	12
17	Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 162-214.	1.3	226
18	Treatment of anxiety disorders. <i>Dialogues in Clinical Neuroscience</i> , 2017, 19, 93-107.	1.8	420

#	ARTICLE	IF	CITATIONS
19	Angststörungen im Alter. , 2017, , 199-217.		0
20	The relevance of "mixed anxiety and depression"™ as a diagnostic category in clinical practice. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 725-736.	1.8	82
21	Biological markers for anxiety disorders, OCD and PTSD " a consensus statement. Part I: Neuroimaging and genetics. World Journal of Biological Psychiatry, 2016, 17, 321-365.	1.3	118
22	Functional MRI activation in response to panic-specific, non-panic aversive, and neutral pictures in patients with panic disorder and healthy controls. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 557-566.	1.8	22
23	Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder. Human Psychopharmacology, 2015, 30, 393-415.	0.7	25
24	Efficacy of treatments for anxiety disorders. International Clinical Psychopharmacology, 2015, 30, 183-192.	0.9	369
25	<i>RGS2</i> genetic variation: Association analysis with panic disorder and dimensional as well as intermediate phenotypes of anxiety. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2015, 168, 211-222.	1.1	26
26	Generalized Anxiety Disorder and Pain. Modern Problems of Pharmacopsychiatry, 2015, 30, 153-165.	2.5	21
27	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences" part 1: general aspects and paradigmatic discussion of depressive disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 5-18.	1.8	23
28	The German guidelines for the treatment of anxiety disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 363-373.	1.8	74
29	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences" part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 87-106.	1.8	26
30	Epidemiology of anxiety disorders in the 21st century. Dialogues in Clinical Neuroscience, 2015, 17, 327-335.	1.8	1,208
31	Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. World Journal of Biological Psychiatry, 2014, 15, 155-166.	1.3	17
32	The Diagnosis of and Treatment Recommendations for Anxiety Disorders. Deutsches Ärztblatt International, 2014, 111, 473-80.	0.6	66
33	Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2014, 28, 403-439.	2.0	511
34	The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm". International Journal of Psychiatry in Clinical Practice, 2013, 17, 78-89.	1.2	8
35	Impaired perceptual processing and conceptual cognition in patients with anxiety disorders: A pilot study with the binocular depth inversion paradigm. Psychology, Health and Medicine, 2013, 18, 363-374.	1.3	6
36	Pharmacological Treatment of Panic Disorder. Modern Problems of Pharmacopsychiatry, 2013, 29, 128-143.	2.5	13

#	ARTICLE	IF	CITATIONS
37	Attachment style, anxiety coping, and personality-styles in withdrawn alcohol addicted inpatients. Substance Abuse Treatment, Prevention, and Policy, 2013, 8, 1.	1.0	73
38	Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with depressive disorder and healthy controls. International Journal of Psychiatry in Clinical Practice, 2013, 17, 56-63.	1.2	4
39	Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies. International Journal of Neuropsychopharmacology, 2013, 16, 1733-1744.	1.0	21
40	The Diagnosis and Treatment of Generalized Anxiety Disorder. Deutsches Ärzteblatt International, 2013, 110, 300-9; quiz 310.	0.6	47
41	In Reply. Deutsches Ärzteblatt International, 2013, 110, 610-1.	0.6	0
42	An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World Journal of Biological Psychiatry, 2012, 13, 510-516.	1.3	56
43	Disorder-Specific Emotional Imagery for Differential and Quantitative Assessment of Agoraphobia. Current Pharmaceutical Design, 2012, 18, 5638-5644.	0.9	2
44	Posttraumatic stress disorder (PTSD) in the German Armed Forces: a retrospective study in inpatients of a German army hospital. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 459-467.	1.8	23
45	Guidelines for the pharmacological treatment of anxiety disorders, obsessiveâ€“compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice, 2012, 16, 77-84.	1.2	327
46	Gender Differences in Associations of Glutamate Decarboxylase 1 Gene (GAD1) Variants with Panic Disorder. PLoS ONE, 2012, 7, e37651.	1.1	20
47	Clinically relevant drug interactions in anxiety disorders. Human Psychopharmacology, 2012, 27, 239-253.	0.7	36
48	TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Molecular Psychiatry, 2011, 16, 647-663.	4.1	130
49	Neuropeptide S receptor geneâ€“converging evidence for a role in panic disorder. Molecular Psychiatry, 2011, 16, 938-948.	4.1	157
50	Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8â€“week placeboâ€“controlled studies. Human Psychopharmacology, 2011, 26, 614-628.	0.7	24
51	Embitterment syndrome: Options for psychopharmacological management. , 2011, , 187-196.		0
52	Borderline personality disorder: A dysregulation of the endogenous opioid system?. Psychological Review, 2010, 117, 623-636.	2.7	108
53	A 2010 Evidence-Based Algorithm for the Pharmacotherapy of Social Anxiety Disorder. Current Psychiatry Reports, 2010, 12, 471-477.	2.1	25
54	Adenosine A2A receptor gene: Evidence for association of risk variants with panic disorder and anxious personality. Journal of Psychiatric Research, 2010, 44, 930-937.	1.5	90

#	ARTICLE	IF	CITATIONS
55	Serotonergic function, substance craving, and psychopathology in detoxified alcohol-addicted males undergoing tryptophan depletion. <i>Journal of Psychiatric Research</i> , 2010, 44, 1163-1169.	1.5	11
56	Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 305.	1.0	116
57	Manifesto for a European Anxiety Disorders Research Network. <i>European Neuropsychopharmacology</i> , 2010, 20, 426-432.	0.3	21
58	Insertion/deletion polymorphism in the gene for angiotensin converting enzyme (ACE) in panic disorder: A gender-specific effect?. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 66-70.	1.3	21
59	A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 904-913.	1.3	59
60	Atypical Anorexia in a Male Patient Accompanied by Strong Obsessive-compulsive Symptoms Successfully Treated with Naltrexone. <i>Pharmacopsychiatry</i> , 2009, 42, 164-165.	1.7	3
61	How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. <i>Human Psychopharmacology</i> , 2009, 24, 269-275.	0.7	51
62	Remission of acute psychotic anxious depression in a patient with Parkinson's disease after treatment with quetiapine. <i>Movement Disorders</i> , 2009, 24, 2431-2432.	2.2	0
63	Neuroimaging in anxiety disorders. <i>Journal of Neural Transmission</i> , 2009, 116, 703-716.	1.4	85
64	Association analysis of Rgs7 variants with panic disorder. <i>Journal of Neural Transmission</i> , 2009, 116, 1523-1528.	1.4	21
65	Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. <i>International Clinical Psychopharmacology</i> , 2009, 24, 87-96.	0.9	82
66	Angsterkrankungen – Panikstörung, soziale und generalisierte Angststörung (ICD-10 F4)., 2009, , 223-240.		0
67	Anxiety symptom severity and functional recovery or relapse. <i>Annals of Clinical Psychiatry</i> , 2009, 21, 81-8.	0.6	9
68	Chromosome 4q31 panic disorder risk locus: Association of neuropeptide Y Y5 receptor variants. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 510-516.	1.1	52
69	Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 1196-1204.	1.1	101
70	Association of polymorphisms in the angiotensin-converting enzyme gene with syndromal panic attacks. <i>Molecular Psychiatry</i> , 2008, 13, 242-243.	4.1	19
71	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 248-312.	1.3	661
72	How are symptom severity and functional recovery/relapse related? An analysis of the escitalopram database. <i>European Psychiatry</i> , 2008, 23, S369.	0.1	0

#	ARTICLE	IF	CITATIONS
73	How to grade categories of evidence. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 242-247.	1.3	22
74	Nocturnal Urinary Cortisol Excretion Over a Randomized Controlled Trial with Paroxetine vs. Placebo Combined with Relaxation Training or Aerobic Exercise in Panic Disorder. <i>Current Pharmaceutical Design</i> , 2008, 14, 3518-3524.	0.9	13
75	The Medical Treatment of Obsessive-Compulsive Disorder and Anxiety. <i>CNS Spectrums</i> , 2008, 13, 37-46.	0.7	40
76	Improvement of Quality of Life in Panic Disorder with Escitalopram, Citalopram, or Placebo. <i>Pharmacopsychiatry</i> , 2007, 40, 152-156.	1.7	33
77	Treatment of Obsessive-Compulsive Disorder. <i>CNS Spectrums</i> , 2007, 12, 28-35.	0.7	23
78	Pharmacological treatment of anxiety disorders - is there a state of the art?. <i>European Psychiatry</i> , 2007, 22, S90.	0.1	0
79	S.21.01 Treatment-resistant panic anxiety disorder. <i>European Neuropsychopharmacology</i> , 2007, 17, S207-S208.	0.3	0
80	Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 769-781.	1.4	95
81	Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. <i>World Journal of Biological Psychiatry</i> , 2007, 8, 175-187.	1.3	131
82	Escitalopram in the treatment of anxiety symptoms associated with depression. <i>Depression and Anxiety</i> , 2007, 24, 53-61.	2.0	39
83	The quantification inventory for somatoform syndromes (QUISS): a novel instrument for the assessment of severity. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 153-163.	1.8	8
84	Trastorno de angustia durante el embarazo y el periodo postparto. <i>European Psychiatry (Ed Espa�ola)</i> , 2007, 14, 44-50.	0.0	0
85	Reply to More on Placebo Response. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1984-1985.	1.1	0
86	Panic disorder during pregnancy and postpartum period. <i>European Psychiatry</i> , 2006, 21, 495-500.	0.1	38
87	Drug treatment for panic disorder. <i>International Congress Series</i> , 2006, 1287, 288-292.	0.2	3
88	Defining Response and Remission in Anxiety Disorders: Toward an Integrated Approach. <i>CNS Spectrums</i> , 2006, 11, 21-28.	0.7	37
89	Rgs 2 gene polymorphisms as modulators of anxiety in humans?. <i>Journal of Neural Transmission</i> , 2006, 113, 1921-1925.	1.4	96
90	Angst â€” Neurobiologie. , 2006, , 483-521.		3

#	ARTICLE	IF	CITATIONS
91	What Is the Threshold for Symptomatic Response and Remission for Major Depressive Disorder, Panic Disorder, Social Anxiety Disorder, and Generalized Anxiety Disorder?. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1428-1434.	1.1	177
92	Which Factors Predict Placebo Response in Anxiety Disorders and Major Depression?. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1741-1746.	1.1	108
93	Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2005, 111, 106-115.	2.2	93
94	Randomized, Double-Blind Study of SR142801 (Osanetant). A Novel Neurokinin-3 (NK3) Receptor Antagonist in Panic Disorder with Pre- and Posttreatment Cholecystokinin Tetrapeptide (CCK-4) Challenges. <i>Pharmacopsychiatry</i> , 2005, 38, 24-29.	1.7	30
95	S.2.6 Treatment of anxiety disorders. <i>European Neuropsychopharmacology</i> , 2005, 15, S96.	0.3	0
96	Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with borderline personality disorder and healthy controls. <i>Psychiatry Research</i> , 2005, 134, 169-179.	1.7	263
97	Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2005, 19, 567-596.	2.0	537
98	Sertraline and exposure therapy in social phobia. <i>British Journal of Psychiatry</i> , 2004, 184, 271-271.	1.7	16
99	Blood Dyscrasias Induced by Psychotropic Drugs. <i>Pharmacopsychiatry</i> , 2004, 37, 70-78.	1.7	54
100	Early traumatic life events, parental rearing styles, family history of mental disorders, and birth risk factors in patients with social anxiety disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 397-405.	1.8	110
101	Treatment-Resistant Panic Disorder. <i>CNS Spectrums</i> , 2004, 9, 725-739.	0.7	54
102	Sertraline Versus Paroxetine in the Treatment of Panic Disorder. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 405-413.	1.1	43
103	Behandlungsprobleme bei Angstpatienten. , 2004, , 547-560.		0
104	5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. <i>European Neuropsychopharmacology</i> , 2003, 13, 153-164.	0.3	40
105	Hyperhomocysteinemia as a new risk factor for brain shrinkage in patients with alcoholism. <i>Neuroscience Letters</i> , 2003, 335, 179-182.	1.0	100
106	WCA Recommendations for the Long-Term Treatment of Obsessive-Compulsive Disorder in Adults. <i>CNS Spectrums</i> , 2003, 8, 7-16.	0.7	103
107	WCA Recommendations for the Long-Term Treatment of Panic Disorder. <i>CNS Spectrums</i> , 2003, 8, 17-30.	0.7	57
108	WCA Recommendations for the Long-Term Treatment of Posttraumatic Stress Disorder. <i>CNS Spectrums</i> , 2003, 8, 31-39.	0.7	41

#	ARTICLE	IF	CITATIONS
109	WCA Recommendations for the Long-Term Treatment of Social Phobia. <i>CNS Spectrums</i> , 2003, 8, 40-52.	0.7	81
110	WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder. <i>CNS Spectrums</i> , 2003, 8, 53-61.	0.7	90
111	Wirksamkeitsuntersuchungen in der Psychotherapieforschung. <i>Verhaltenstherapie</i> , 2002, 12, 205-215.	0.3	10
112	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. <i>World Journal of Biological Psychiatry</i> , 2002, 3, 171-199.	1.3	155
113	Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with panic disorder. <i>Comprehensive Psychiatry</i> , 2002, 43, 269-278.	1.5	93
114	Assessing the severity of panic disorder and agoraphobia. <i>Journal of Anxiety Disorders</i> , 2002, 16, 331-340.	1.5	10
115	Smoking Modulates Neuroendocrine Responses to Ipsapirone in Patients with Panic Disorder. <i>Neuropsychopharmacology</i> , 2002, 27, 270-278.	2.8	12
116	"As needed" pharmacotherapy combined with stimulus control treatment in chronic insomnia--assessment of a novel intervention strategy in a primary care setting. <i>Annals of Clinical Psychiatry</i> , 2002, 14, 1-7.	0.6	10
117	Separation Anxiety and Actual Separation Experiences during Childhood in Patients with Panic Disorder. <i>Canadian Journal of Psychiatry</i> , 2001, 46, 948-952.	0.9	47
118	Effect of aerobic exercise on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine and to ipsapirone in untrained healthy subjects. <i>Psychopharmacology</i> , 2001, 155, 234-241.	1.5	43
119	Clozapine-associated elevation of plasma cholinesterase. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001, 251, 269-271.	1.8	5
120	Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. <i>International Clinical Psychopharmacology</i> , 2000, 15, 153-161.	0.9	44
121	Plasma homocysteine is a predictor of alcohol withdrawal seizures. <i>NeuroReport</i> , 2000, 11, 2749-2752.	0.6	73
122	Polymorphism of the gene of angiotensin converting enzyme: lack of association with mood disorder. <i>Journal of Neural Transmission</i> , 2000, 107, 1361-1366.	1.4	49
123	Salivary, total plasma and plasma free cortisol in panic disorder. <i>Journal of Neural Transmission</i> , 2000, 107, 831-837.	1.4	59
124	Salivary Cortisol in Panic Attacks. <i>American Journal of Psychiatry</i> , 2000, 157, 454-456.	4.0	81
125	The Use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial. <i>Pharmacopsychiatry</i> , 2000, 33, 174-181.	1.7	55
126	Myocarditis Associated with Clozapine Treatment. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, 880-880.	1.3	35

#	ARTICLE	IF	CITATIONS
127	Diurnal variation of cortisol in panic disorder. <i>Psychiatry Research</i> , 2000, 95, 245-250.	1.7	51
128	FC04.01 Responsiveness of central serotonin receptors in panic disorder: Effects of clomipramine treatment and exercise. <i>European Psychiatry</i> , 2000, 15, 243s-243s.	0.1	0
129	Myocarditis associated with clozapine treatment. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, 880-880.	1.3	3
130	Application of a new statistical approach to evaluate a clinical trial with panic disorder patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999, 249, 21-27.	1.8	11
131	Decreased Neuroendocrine Responses to Meta-Chlorophenylpiperazine (m-CPP) but Normal Responses to Ipsapirone in Marathon Runners. <i>Neuropsychopharmacology</i> , 1999, 20, 150-161.	2.8	43
132	Rebound insomnia after hypnotic withdrawal in insomniac outpatients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998, 248, 148-156.	1.8	32
133	Zur sozialen Situation schizophrener Patienten. <i>Der Nervenarzt</i> , 1998, 69, 204-209.	5.0	39
134	The use of the Panic and Agoraphobia Scale in a clinical trial. <i>Psychiatry Research</i> , 1998, 77, 43-49.	1.7	52
135	The application of the panic and Agoraphobia Scale (P & A) in clinical trials. <i>European Psychiatry</i> , 1998, 13, 283s-283s.	0.1	0
136	Endurance Training in Panic Patients: Spiroergometric and Clinical Effects. <i>International Journal of Sports Medicine</i> , 1998, 19, 496-502.	0.8	24
137	The Use of Parametric vs. Nonparametric Tests in the Statistical Evaluation of Rating Scales. <i>Pharmacopsychiatry</i> , 1998, 31, 222-224.	1.7	15
138	Fluvoxamine or Placebo in the Treatment of Panic Disorder and Relationship to Blood Concentrations of Fluvoxamine. <i>Pharmacopsychiatry</i> , 1998, 31, 117-121.	1.7	25
139	Comparison of Aerobic Exercise, Clomipramine, and Placebo in the Treatment of Panic Disorder. <i>American Journal of Psychiatry</i> , 1998, 155, 603-609.	4.0	286
140	The QT interval and the atypical antipsychotic, sertindole. <i>International Journal of Psychiatry in Clinical Practice</i> , 1998, 2, 265-273.	1.2	20
141	Safety and tolerance of zolpidem in the treatment of disturbed sleep. <i>International Clinical Psychopharmacology</i> , 1998, 13, 157-168.	0.9	70
142	Urinary Excretion of Cortisol, Norepinephrine, Testosterone, and Melatonin in Panic Disorder. <i>Pharmacopsychiatry</i> , 1997, 30, 113-117.	1.7	28
143	Exercise Avoidance and Impaired Endurance Capacity in Patients with Panic Disorder. <i>Neuropsychobiology</i> , 1997, 36, 182-187.	0.9	53
144	Parallel increase of heterochromatic increment threshold and postadaptation thresholds in Parkinson's disease and in neuroleptic treatment. <i>Vision Research</i> , 1997, 37, 3535-3547.	0.7	10

#	ARTICLE	IF	CITATIONS
145	Panic disorder – acceptance of the diagnostic entity and treatment modalities preferred by German health professionals. <i>European Psychiatry</i> , 1996, 11, 298-305.	0.1	3
146	Nocturnal plasma melatonin levels after flunitrazepam administration in healthy subjects. <i>European Neuropsychopharmacology</i> , 1996, 6, 149-153.	0.3	34
147	Cardio-respiratory and other symptom clusters in panic disorder. <i>Anxiety</i> , 1996, 2, 99-101.	0.5	32
148	Nocturnal Melatonin Secretion and Sleep after Doxepin Administration in Chronic Primary Insomnia. <i>Pharmacopsychiatry</i> , 1996, 29, 187-192.	1.7	59
149	Assessing the efficacy of treatments for panic disorder and agoraphobia. I. Methodological problems. <i>International Clinical Psychopharmacology</i> , 1995, 10, 83-94.	0.9	36
150	Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. <i>International Clinical Psychopharmacology</i> , 1995, 10, 73-82.	0.9	263
151	What treatments do patients with panic disorder and agoraphobia get?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1995, 245, 165-171.	1.8	19
152	Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. <i>Journal of Pineal Research</i> , 1995, 19, 116-122.	3.4	109
153	Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia. <i>European Psychiatry</i> , 1995, 10, 173s-179s.	0.1	5
154	Myocarditis under therapy with clozapine. <i>Schizophrenia Research</i> , 1995, 17, 293-294.	1.1	42
155	Depressive syndromes in schizophrenic patients under neuroleptic therapy. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1992, 241, 291-295.	1.8	29
156	Intermittent Medication, Coping and Psychotherapy Interactions in Relapse Prevention and Course Modification. <i>British Journal of Psychiatry</i> , 1992, 161, 140-144.	1.7	5
157	Depressive syndromes in schizophrenic patients after discharge from hospital. <i>European Archives of Psychiatry and Neurological Sciences</i> , 1990, 240, 113-120.	0.9	36